The trial results support Tukysa-Herceptin-Perjeta as yet another option for breast cancer patients in the frontline ...

Long-term follow-up in the PALLAS study showed no overall survival benefit with palbociclib plus endocrine therapy compared to endocrine therapy alone in hormone receptor-positive, HER2-negative ...

Abemaciclib monotherapy benefited 33% of patients with HR-positive, HER2-negative breast cancer post-CDK4/6 inhibitor progression. Abemaciclib shows promise as a monotherapy for HR-positive, ...

A new Tufts study found that Medicare price negotiations on biologics with imminent biosimilars could lead to near-term savings, but greater savings are likely from biosimilar competition.

Trastuzumab deruxtecan (T-DXd; Enhertu), is a HER2-targeting ADC that is used in ET-treated HER2-low or HER2-ultralow disease and offered meaningful results in DESTINY-Breast04. In a 2025 real-world ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Swiss pharma giant Roche’s Itovebi (inavolisib (for the treatment of adults with a type of breast cancer called ...

With the second round of IRA negotiations having been conducted under the Trump administration, GlobalData life sciences ...

CMS has negotiated a 71% discount off the list price, or $274 for a 30-day supply, on Novo Nordisk’s semaglutide products — Ozempic and Rybelsus for diabetes and Wegovy for weight loss — through the ...

Dawn Klemow, MD, assistant clinical professor, University of Texas Southwestern Medical Center, previews some of the most recent advances in breast cancer treatment. Recent innovations in breast ...

On Thursday, Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) announced results from the Phase 3 PATINA trial. The trial demonstrated that the addition of IBRANCE (palbociclib) to ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved inavolisib as part of combination therapy for certain adults with breast cancer. The indication ...